Cargando…
A systematic review and meta-analysis of selected toxicity endpoints of alpelisib
Purpose: Alpelisib is a first-in-class α-specific phosphatidylinositol 3-kinase inhibitor approved for the treatment of patients with estrogen receptor–positive metastatic breast cancer. High absolute risk (AR) of relevant toxicities has been observed with this treatment. This meta-analysis aimed to...
Autores principales: | Shields, Misty, Mo, Qianxing, Armitage, Melissa, Sharpe, Susan C., Costa, Ricardo L.B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584237/ https://www.ncbi.nlm.nih.gov/pubmed/33144920 http://dx.doi.org/10.18632/oncotarget.27770 |
Ejemplares similares
-
Diabetic Ketoacidosis With Alpelisib
por: Jeun, Rebecca, et al.
Publicado: (2021) -
Alpelisib for breast cancer
Publicado: (2022) -
Alpelisib-Induced Diabetic Ketoacidosis
por: Espinosa, Luis Borges, et al.
Publicado: (2021) -
Alpelisib-Induced Diabetic Ketoacidosis
por: Nguyen, Paul, et al.
Publicado: (2021) -
Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
por: Shaker, Mohamed E., et al.
Publicado: (2023)